BMJ Open Correlations of chlamydia and gonorrhoea among pharyngeal, rectal and urethral sites among Thai men who have sex with men: multicentre community-led test and treat cohort in Thailand

Akarin Hiransuthikul,¹ Thanthip Sungsing,¹ Jureeporn Jantarapakde,¹ Deondara Trachunthong,¹ Stephen Mills,² Ravipa Vannakit,³ Praphan Phanuphak,¹ Nittaya Phanuphak¹

To cite: Hiransuthikul A, Sungsing T, Jantarapakde J, et al. Correlations of chlamydia and gonorrhoea among pharyngeal, rectal and urethral sites among Thai men who have sex with men: multicentre community-led test and treat cohort in Thailand. *BMJ Open* 2019;**9**:e028162. doi:10.1136/bmjopen-2018-028162

► Prepublication history and additional material for this paper are available online. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2018-028162>).

Received 26 November 2018

Revised 30 May 2019

Accepted 10 June 2019

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹PREVENTION, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

²LINKAGES Thailand FHI360, Bangkok, Thailand

³Office of Public Health, United States Agency for International Development, Bangkok, Thailand

Correspondence to

Dr Akarin Hiransuthikul;
ahiransuthikul@gmail.com

ABSTRACT

Objective Routine screening for *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) infections in sexually exposed anatomical sites may be challenging in resource-limited settings. The objective of this study was to determine the proportion of missed CT/NG diagnoses if a single anatomical site screening was performed among men who have sex with men (MSM) by examining the pattern of anatomical sites of CT/NG infections.

Methods Thai MSM were enrolled to the community-led test and treat cohort. Screening for CT/NG infections was performed from pharyngeal swab, rectal swab and urine using nucleic acid amplification testing. The correlations of CT/NG among the three anatomical sites were analysed.

Results Among 1610 MSM included in the analysis, 21.7% had CT and 15.5% had NG infection at any anatomical site. Among those tested negative for CT or NG infection at either pharyngeal, rectal or urethral site, 8%–19% had CT infection and 7%–12% had NG infection at the remaining two sites. Of the total 349 CT infections, 85.9%, 30.6% and 67.8% would have been missed if only pharyngeal, rectal or urethral screening was performed, respectively. Of the total 249 NG infection, 55.7%, 39.6% and 77.4% would have been missed if only pharyngeal, rectal or urethral screening was performed, respectively. The majority of each anatomical site of CT/NG infection was isolated to their respective site, with rectal site having the highest proportion of isolation: 78.9% of rectal CT and 62.7% of rectal NG infection.

Conclusions A high proportion of CT/NG infections would be missed if single anatomical site screening was performed among MSM. All-site screening is highly recommended, but if not feasible, rectal screening provides the highest yield of CT/NG diagnoses. Effort in lowering the cost of the CT/NG screening test or developing affordable molecular technologies for CT/NG detection is needed for MSM in resource-limited settings.

Strengths and limitations of this study

- The study includes a large number of sexually active men who have sex with men (MSM) who completed *Chlamydia trachomatis* (CT)/*Neisseria gonorrhoeae* (NG) screening in all three anatomical sites based on their self-reported sexually exposed contact routes.
- Correlations of CT/NG infections among pharyngeal, rectal and urethral sites among sexually active MSM were identified, and showed the proportion of missed diagnoses if single anatomical site screening was performed.
- Because CT/NG screening in our study was based on self-reported sexually exposed contact routes, we were unable to compare the performance between a history-based and universal approach.
- Extragenitalia samples from a modest number of participants may have been missed due to social desirability bias regarding questions about the site(s) of sexual contact.

Trial Registration Number NCT03580512; Results.

INTRODUCTION

Chlamydia trachomatis (CT) and *Neisseria gonorrhoeae* (NG) infections are among the most common bacterial sexually transmitted infections (STIs) and disproportionately affect men who have sex with men (MSM) worldwide.¹ Two large studies conducted in Thailand between 2006 and 2010 showed that MSM had approximately 30% higher prevalence of CT infection and up to five times higher prevalence of NG infection compared with men who have sex exclusively with women.^{2 3}

CT/NG infections are associated with acquiring and transmitting HIV infection.⁴ In particular, rectal CT/NG infection is strongly associated with an increased risk of HIV acquisition among MSM.^{5–6} And while the impact of pharyngeal infection towards HIV acquisition is less understood, it is highly prevalent and may, therefore, serve as an important for infection at genital sites.^{7–9} Since CT/NG infections are often asymptomatic,¹⁰ the lack of routine screening may result in a missed opportunity to diagnosis these curable STIs.

The diagnosis of CT/NG infections, both at genital and extragenital sites, can be made using nucleic acid amplification tests (NAATs). Many studies have shown superior sensitivity and specificity of NAATs in detecting extragenital CT/NG infection compared with culture.^{11–14} The findings prompted the US Center for Disease Control and Prevention (CDC) to recommend the use of NAATs for pharyngeal and rectal CT/NG screening,¹⁵ although they have not been cleared by the US Food and Drug Administration.

Frequency of testing and anatomical sites to be tested are the two factors to consider in asymptomatic CT/NG screening. The CDC STD treatment guideline recommends that all sexually active MSM should be screened at least annually at sites of contact regardless of condom use.¹⁵ More frequent screening is advised if the individuals are at increased risk. Conversely, the Australian STI management guideline recommends screening at all sites regardless of sexually exposed contact routes.¹⁶ However, many barriers prevent the implementation of these recommendations in clinical practice. For the clients, these barriers may include the cost of tests, underestimating the risk of asymptomatic infections and concern of being stigmatised.^{17–18} Healthcare providers also often lack knowledge on the importance of STI screening at appropriate anatomical sites,¹⁷ which may also be the case in Thailand where there are currently no consensus recommendations for CT/NG screening.

Our primary objective was to determine the proportion of missed CT/NG diagnoses if a single anatomical site screening was performed among MSM by examining the pattern of anatomical sites of CT/NG infections. Other objectives were to determine the prevalence of CT/NG infections among MSM enrolled in the community-led test and treat cohort and to examine the prevalence of CT/NG infections in the remaining two anatomical sites if one site was negative to evaluate the proportion of missed diagnoses per individual. The findings from our study will be crucial in guiding the recommendations for CT/NG screening among MSM, both in HIV treatment and prevention programmes, in resource-limited settings.

METHODS

Enrolment of participants

The present study used data from MSM participants enrolled in the community-led test and treat cohort between October 2015 and October 2016. The

community-led test and treat cohort aimed to evaluate the feasibility of empowering lay providers who are members of MSM and transgender women (TGW) communities to provide HIV-related services, increasing uptake of HIV testing and treatment services among MSM and TGW in Thailand.

Eligible criteria and study procedures for the community-led test and treat cohort have been reported in detail elsewhere.¹⁹ In brief, adults Thai MSM and TGW with a history of at least one unprotected anal sexual intercourse with a man in the past 6 months were enrolled from Service Workers IN Group drop-in centres (DICs) in Bangkok and Pattaya city, Rainbow Sky Association of Thailand DICs in Bangkok and Songkhla, Caremat DIC in Chiang Mai and Sisters DIC in Pattaya city, Thailand for an 18-month follow-up period. Only participants of unknown HIV status were enrolled, and those with known HIV infection were excluded from enrolment. Screening for CT and NG was performed at enrolment using NAAT (Abbott Real Time CT/NG, Abbott Molecular, Illinois, USA) from pharyngeal swab, rectal swab and/or urine collection based on the self-report sexually exposed contact routes. Participants who completed both CT and NG screening in all three anatomical sites at baseline were included in this analysis.

All participants gave informed consent.

Statistical analysis

Statistical analysis was performed using Stata 13 (StataCorp LP, College Station, Texas, USA). Demographic, CT/NG and HIV testing results, and sexual risk behaviours were summarised as median (IQR) and number (percentage) for continuous and categorical variables, respectively. Characteristics between HIV-positive and HIV-negative participants were compared using a χ^2 or Fisher's exact test, or Mann-Whitney test as appropriate.

The distribution of anatomical sites of CT/NG infections at baseline was analysed to determine the proportion (prevalence with 95% CI) of missed CT/NG diagnoses per individual if single anatomical site screening was performed, pattern of anatomical distribution for all CT/NG infections and pattern of anatomical distribution of CT/NG infections by anatomical site. Statistical significance was defined as p value of <0.05.

Participant and public involvement

Neither participants nor public were directly involved in the development, design or recruitment of the study.

RESULTS

Participant characteristics

Of 1858 MSM enrolled in the community-led test and treat cohort, a total of 1610 (86.7%) participants completed both CT and NG testing in all three anatomical sites at baseline based on their self-reported sexually exposed contact routes and were included in the analysis. Compared with MSM who did not complete CT/NG

Table 1 Demographic of 1610 men who have sex with men included in the analysis

Characteristics	Overall (n=1610)		HIV positive (n=303)		HIV negative (n=1307)		P value
	n	%	n	%	n	%	
Median age (IQR) years	24.1 (20.8–30.0)		24.1 (21.0–28.7)		24.1 (20.8–30.5)		0.48
Site							<0.001
Bangkok	676	42.0	164	54.1	512	39.2	
Chiang Mai	541	33.6	61	20.1	480	36.7	
Hat Yai	152	9.4	17	5.6	135	10.3	
Pattaya city	241	15.0	61	20.1	180	13.8	
Marital status							0.19
Single	1158/1598	72.5	218/301	72.4	940/1297	72.5	
Living together with male partner	381/1598	23.8	77/301	25.6	304/1297	23.4	
Married to a woman	59/1598	3.7	6/301	2.0	53/1297	4.1	
Highest education							0.46
Lower than high school	325/1594	20.4	68/299	22.7	257/1295	19.9	
High school	638/1594	40.0	120/299	40.1	518/1295	40.0	
Higher than high school	631/1594	39.6	111/299	27.1	520/1295	40.2	
Main occupation							0.06
Unemployed	97/1598	6.1	25/300	8.3	72/1298	5.6	
Student	486/1598	30.4	76/300	25.3	410/1298	31.6	
Sex worker	707/1598	44.2	133/300	44.3	574/1298	44.2	
Employed, other than sex worker	308/1598	19.3	66/300	22.0	242/1298	18.6	
Income>10 000 THB (US\$320) per month	672/1383	48.6	124/264	47.0	548/1119	49.0	0.56
Median age (IQR) of first sexual intercourse	17 (15–19)		17 (15–19)		17 (15–19)		0.22
Male circumcision	186/1391	13.4	25/240	10.4	161/1151	14.0	0.14
Number of sexual partners in the past 6 months							0.34
No sexual partner	30/1603	1.9	7/300	2.3	23/1303	1.8	
Single partner	308/1603	19.2	59/300	19.7	249/1303	19.1	
Multiple partners	870/1603	54.3	150/300	50.0	720/1303	55.3	
Refuse to answer	395/1603	24.6	84/300	28.0	311/1303	23.9	
Unprotected sex in the past 6 months	1261/1586	79.5	252/298	84.6	1009/1288	78.3	0.02
Illicit drug used in the past 6 months	599/1530	39.2	100/278	36.0	499/1252	39.9	0.23
Self-reported STIs in the past 6 months							<0.001
No	977/1546	63.2	146/291	50.2	831/1255	66.2	
Yes	106/1546	6.9	21/291	7.2	85/1255	6.8	
Not sure	463/1546	29.9	124/291	42.6	339/1255	27.0	
Group sex in the past 6 months	207/1520	13.6	47/286	16.4	160/1234	13.0	0.12
Overall CT infections	349	21.7	111	36.6	238	18.2	<0.001
Pharyngeal CT	48	3.0	17	5.6	31	2.4	0.003
Rectal CT	242	15.0	88	29.0	154	11.8	<0.001
Urethral CT	112	7.0	29	9.6	83	6.4	0.04
Overall NG infections	249	15.5	91	30.0	158	12.1	<0.001
Pharyngeal NG	110	6.8	25	8.3	85	6.5	0.28
Rectal NG	150	9.3	68	22.4	82	6.3	<0.001
Urethral NG	56	3.5	22	7.3	34	2.6	<0.001

CT, *Chlamydia trachomatis*; NG, *Neisseria gonorrhoeae*; STIs, sexually transmitted infections; THB, Thai baht.

Table 2 Prevalence of *Chlamydia trachomatis* infections at the remaining two sites among men who have sex with men who had negative result at pharyngeal, rectal and urethral sites, respectively

Negative site	Positive site	Prevalence (95% CI)			P value
		Overall	HIV positive	HIV negative	
Pharyngeal (n=1562)	Rectal (n=223)	14.3 (12.6 to 16.1)	27.6 (22.5 to 33.2)	11.3 (9.6 to 13.2)	<0.001
	Urethral (n=110)	7.0 (5.8 to 8.4)	10.1 (6.9 to 14.2)	6.4 (5.1 to 7.8)	0.02
	Rectal or urethral (n=301)	19.3 (17.3 to 21.3)	32.9 (27.5 to 38.6)	16.2 (14.2 to 18.4)	<0.001
Rectal (n=1368)	Pharyngeal (n=29)	2.1 (1.4 to 3.0)	3.7 (1.6 to 7.2)	1.8 (1.1 to 2.8)	0.08
	Urethral (n=79)	5.8 (4.6 to 7.2)	7.0 (4.0 to 11.2)	5.6 (4.3 to 7.0)	0.41
	Pharyngeal or urethral (n=107)	7.8 (6.5 to 9.4)	10.7 (6.9 to 15.6)	7.3 (5.9 to 8.9)	0.09
Urethral (n=1498)	Pharyngeal (n=46)	3.1 (2.3 to 4.1)	6.2 (3.7 to 9.7)	2.4 (1.6 to 3.4)	0.001
	Rectal (n=209)	14.0 (12.2 to 15.8)	27.0 (21.8 to 32.7)	11.0 (9.3 to 12.9)	<0.001
	Pharyngeal or rectal (n=237)	15.8 (14.0 to 17.8)	29.9 (24.6 to 35.7)	12.7 (10.9 to 14.7)	<0.001

testing in all three anatomical sites, MSM who completed CT/NG testing in all three anatomical sites had higher prevalence of CT/NG infections at any anatomical sites (29.9% vs 16.4%, $p<0.001$) and reported higher sexual risk behaviours (online supplementary file 1).

At enrolment, the prevalence of CT/NG infections at any anatomical sites was 29.9%: 21.7% for CT infection and 15.5% for NG infection. The most prevalent CT/NG infections by anatomical sites were rectal CT (15.0%), rectal NG (9.3%) and urethral CT (7.0%). HIV-positive participants had significantly higher prevalence of both CT and NG infections in all anatomical sites, except for pharyngeal NG, and were more likely than HIV-negative participants to be enrolled from the Bangkok sites, self-perceived high risk of HIV transmission in the past month, had unprotected sex in the past month and self-reported or unsure of having STIs in the past month (table 1).

The proportion of missed CT/NG diagnoses per individual if single anatomical site screening was performed

Among participants who tested negative for CT infection at pharyngeal, rectal or urethral sites, 19.3%, 7.8%

or 15.8% had CT infection in any of the remaining two sites, respectively (table 2). HIV-positive MSM had significantly higher prevalence of CT infection in any of the remaining two sites among those who tested negative for pharyngeal (32.9% vs 16.2%, $p<0.001$) or urethral CT (29.9% vs 12.7%, $p<0.001$) compared with HIV-negative MSM. Among those who tested negative for NG infection at pharyngeal, rectal or urethral site, 9.3%, 6.8% or 12.4% had NG infection in any of the remaining two sites, respectively (table 3). HIV-positive MSM had significantly higher prevalence of NG infection in any of the remaining two sites across all anatomical sites tested negative (23.7% vs 6.0%, $p<0.001$ among those who tested negative for pharyngeal NG; 9.6% vs 6.2%, $p=0.045$ among those who tested negative for rectal NG; and 24.6% vs 9.7%, $p<0.001$ among those who tested negative for urethral NG).

Pattern of anatomical distribution for all CT/NG infections

Of the total 349 CT infections in our study, 8.0% were isolated to pharyngeal site, 54.7% to rectal site and 22.4% to urethral site (figure 1). On the basis of our data, 85.9%, 30.6% and 67.8% of the total CT infections in our study would have been missed if only pharyngeal, rectal

Table 3 Prevalence of *Neisseria gonorrhoeae* infections at the remaining two sites among men who have sex with men who had negative result at pharyngeal, rectal and urethral sites, respectively

Negative site	Positive site	Prevalence (95% CI)			P value
		Overall	HIV positive	HIV negative	
Pharyngeal (n=1500)	Rectal (n=108)	7.2 (5.9 to 8.6)	20.5 (15.9 to 25.7)	4.2 (3.1 to 5.5)	<0.001
	Urethral (n=45)	3.0 (2.2 to 4.0)	6.1 (3.6 to 9.6)	2.3 (1.5 to 3.3)	0.001
	Rectal or urethral (n=139)	9.3 (7.8 to 10.8)	23.7 (18.9 to 29.2)	6.0 (4.7 to 7.5)	<0.001
Rectal (n=1460)	Pharyngeal (n=68)	4.7 (3.6 to 5.9)	6.0 (3.3 to 9.8)	4.4 (3.3 to 5.7)	0.30
	Urethral (n=36)	2.5 (1.7 to 3.4)	4.3 (2.1 to 7.7)	2.1 (1.4 to 3.1)	0.05
	Pharyngeal or urethral (n=99)	6.8 (5.5 to 8.2)	9.8 (6.3 to 14.3)	6.2 (4.9 to 7.7)	0.045
Urethral (n=1554)	Pharyngeal (n=99)	6.4 (5.2 to 7.7)	7.1 (4.4 to 10.8)	6.2 (4.9 to 7.7)	0.57
	Rectal (n=130)	8.4 (7.0 to 9.9)	19.9 (15.4 to 25.1)	5.8 (4.6 to 7.2)	<0.001
	Pharyngeal or rectal (n=193)	12.4 (10.8 to 14.2)	24.6 (19.6 to 30.0)	9.7 (8.2 to 11.5)	<0.001

or urethral screening was performed, respectively. Of the total 249 NG infections, 25.3%, 37.8% and 12.5% were isolated to pharyngeal, rectal and urethral sites, respectively (figure 2). Collectively, 55.7%, 39.6% and 77.4% of NG infections would have been missed if only pharyngeal, rectal or urethral screening was performed, respectively.

Pattern of anatomical distribution of CT/NG infections by anatomical site

Rectal site was the most isolated site of CT/NG infection: 191 out of 242 (78.9%) rectal CT infection and 94 out of 150 rectal NG infection were isolated to rectum (figures 1 and 2). Importantly, the majority of each anatomical site of CT/NG infection was isolated to their respective site: 58.3% and 57.3% for pharyngeal CT and NG infection, respectively, and 69.6% and 55.4% for urethral CT and NG infection, respectively.

DISCUSSION

We examined the pattern of anatomical sites of CT/NG infections and showed that among MSM who tested negative for CT or NG infection at either pharyngeal, rectal or urethral site, 8%–19% had CT infection and 7%–12% had NG infection at the remaining two sites. Of the 349 CT infections, 8.0% were isolated to pharyngeal site, 54.7% to rectal site and 22.4% to urethral site; and 85.9%, 30.6% and 67.8% of the total CT infections would have been missed if only pharyngeal, rectal or urethral screening was performed, respectively. Of the 249 NG infections, 25.3%, 37.8% and 12.5% were isolated to pharyngeal, rectal and urethral sites, respectively; and 55.7%, 39.6% and 77.4%

of NG infections would have been missed if only pharyngeal, rectal or urethral screening was performed, respectively. The majority of each anatomical site of CT/NG infection was isolated to their respective site, with rectal site having the highest proportion of isolation: 78.9% of rectal CT and 62.7% of rectal NG infection. These data suggest that screening at all self-report sexually exposed contact routes is highly recommended. However, if this is not feasible, screening at rectal site would provide the highest yield of CT/NG diagnoses.

The overall prevalence CT/NG infections at any anatomical sites in our cohort was comparable to the historical Thai facility-based test and treat cohort which enrolled previously unknown HIV-status Thai adult MSM and TGW with similar risk behaviours in 2012 (21.4% for CT and 12.4% for NG infection).²⁰ The prevalence of CT/NG infections per each anatomical site in our study was comparable to one of the largest studies tested for pharyngeal, rectal and urethral CT/NG infections based on their self-reported exposure conducted in San Francisco between 2010 and 2011. Among 3039 MSM enrolled, the prevalence of pharyngeal, rectal and urethral CT infections was 2.3%, 11.9% and 4.4%, respectively; and 6.5%, 9.7%, and 5.5% for pharyngeal, rectal and urethral NG infections, respectively.²¹

To the best of our knowledge, our study was among the first to report the proportion of missed CT/NG diagnoses per individual if single anatomical site screening was performed. Supposing that one anatomical site screening was performed, 8%–19% of MSM who tested negative for CT infection and 7%–12% of those tested negative for NG infection actually had CT and NG infections at the

No. of participants (%) with CT infections			
Type(s) of infection	Pharyngeal (n = 48)	Rectal (n = 242)	Urethral (n = 112)
Isolated site	28 (58.3)	191 (78.9)	78 (69.6)
Multiple sites			
Pharyngeal and rectal	18 (37.5)	18 (7.4)	-
Pharyngeal and urethral	1 (2.1)	-	1 (0.9)
Rectal and urethral	-	32 (13.2)	32 (28.6)
All 3 sites	1 (2.3)	1 (0.4)	1 (0.9)

Abbreviations: CT, *Chlamydia trachomatis*

Figure 1 Distribution of *Chlamydia trachomatis* (CT) infections (n=349) by anatomical site.

No. of participants (%) with NG infections			
Type(s) of infection	Pharyngeal (n = 110)	Rectal (n = 150)	Urethral (n = 56)
Isolated site	63 (57.3)	94 (62.7)	31 (55.4)
Multiple sites			
Pharyngeal and rectal	36 (32.7)	36 (24.0)	-
Pharyngeal and urethral	5 (4.6)	-	5 (8.9)
Rectal and urethral	-	14 (9.3)	14 (25.0)
All 3 sites	6 (5.7)	6 (4.2)	6 (11.5)

Abbreviations: NG, *Neisseria gonorrhoeae*

Figure 2 Distribution of *Neisseria gonorrhoeae* (NG) infections (n=249) by anatomical site.

remaining two anatomical sites, respectively. Importantly, the proportion of these potential missed CT/NG diagnoses increased to 11%–33% for CT and 10%–25% for NG infection among newly diagnosed HIV-positive MSM. This may be because of a higher proportion of unprotected sex and self-reported STIs in the past 6 months among HIV-positive MSM compared with HIV-negative MSM. These results point out the importance of CT/NG screening at all self-report sexually exposed contact routes. However, if resource limits the number of sites screened, rectal site proves to be the site of choice for screening, with less than 10% showed any infection in the remaining two anatomical sites if tested negative.

A study conducted in San Francisco in 2003, in which NAATs were used to test MSM for chlamydia and gonorrhoea at all three anatomical sites, was among the first published studies to show that the majority of CT (53%) and NG (64%) infections were at non-urethral sites, and would have been missed if only urethral screening was performed.¹⁰ More recent published data from multisite in USA and the Netherlands showed a range of 43%–69% of extragenital CT infection and 46%–76% of extragenital NG infection would have been missed if only urethral screening was performed, which were in line to our findings.^{21–24} Data from the San Francisco's STD clinic between 2008 and 2009 showed that if one anatomical site screening was performed, screening only the pharynx would miss 81% of CT infection and 32% of NG infection; and screening only the rectum would miss 23% of CT infection and 52% of NG infection.²⁵ Regardless of our similar findings that rectal site screening would miss the fewest infections, the high proportion of potential missed diagnoses if a single anatomical site screening was performed in any of the three sites supports the critical need for all sites, at least depending on self-reported sexually exposed contact routes, among MSM.

Although CT/NG infections at each anatomical site possess distinct characteristics, such as clinical manifestations, different duration of infections, and concerns over drug-resistant pathogens,^{26 27} the most important thing is the ability to detect and treat those infections regardless of site. Due to their asymptomatic nature, many patients may not be aware of the importance of the infections and do not seek medical advice.¹⁸ Healthcare provider can take the lead in encouraging sexually active MSM to screen for CT/NG infections, at least depending on their self-reported site of exposure, as the first step towards detecting and providing timely screening and treatment towards preventing transmission in the community.

Nonetheless, the cost of the test could be a major obstacle in implementing this recommendation resource-limited settings. For instance, the current cost of NAAT test for CT/NG infections in Thailand is approximately US\$30 per anatomical site. This is considered expensive since more than half of our MSM participants have monthly income of less than US\$320. To reduce the cost of test, a strategy to test pooled specimen has been made with promising results.²⁸ Effort in lowering the cost of the CT/

NG screening test or developing affordable molecular technologies for CT/NG detection is needed for MSM in resource-limited settings.

Certain limitations need to be considered. First, sexual behaviours were assessed using a self-administered paper questionnaire. While self-administered questionnaires may improve disclosure of sensitive behaviours, actual risk behaviours may still be under-reported. Second, risk behaviours were captured within the past 6 months. Because CT and NG infections have a long duration of infection, capturing risk behaviours within the past 6 months was beneficial in assessing risk behaviours since the potential contact date of the infections. However, the relatively long recall period may lead to recall bias. Third, because CT/NG screening in our study was based on self-reported sexually exposed contact routes rather than universal screening at all sites, we were unable to compare the performance between a history-based and universal approach. Furthermore, by limiting our analysis to MSM who self-reported sexual contact in all three anatomical sites, the findings may be biased towards those with higher risks which may have led to an overestimation of prevalence of CT/NG infections in our sample. Finally, we may have missed extragenitalia samples from a modest number of participants (248 MSM (13.4% of total MSM enrolled)) due to social desirability bias regarding questions about the site(s) of sexual contact.

Our study found that a high proportion of CT/NG infections would have been missed among MSM if single anatomical site screening is performed, especially among HIV-positive MSM. We recommend that all-site screening should be performed among MSM, at least based on self-reported sexually exposed contact routes. However, if this is not feasible, rectal screening provides the highest yield of CT/NG diagnoses. Effort in lowering the cost of the CT/NG screening test or developing affordable molecular technologies for CT/NG detection is needed for MSM in resource-limited settings.

Acknowledgements The authors would like to express their sincere thanks to all participants and study staff. This work was made possible by the United States Agency for International Development (USAID) and the United States President's Emergency Plan for AIDS Relief (PEPFAR). The contents are the responsibility of the LINKAGES project and do not necessarily reflect the views of USAID, PEPFAR or the United States Government.

Contributors AH interpreted the data, drafted the manuscript and performed statistical analysis. TS and JJ coordinated the study and oversaw data management. DT gave advised on statistical analysis and performed statistical analysis. TS, JJ, SM, RV and NP designed and conducted the study. NP advised on the analysis plan. NP and PP led the study. All authors critically reviewed and approved the final draft of manuscript.

Funding Funding for this project was supported through LINKAGES, a five-year cooperative agreement (AID-OAA-A-14-00045), which is led by FHI 360 in partnership with IntraHealth International, Pact, and the University of North Carolina at Chapel Hill.

Competing interests None declared.

Patient consent for publication Obtained.

Ethics approval The study (NCT03580512) was approved by the institutional review boards of the Faculty of Medicine, Chulalongkorn University (IRB No. 181/57), the Department of Disease Control, Thai Ministry of Public Health (IRB

No. 9/57-678), the Provincial Health Offices of Chonburi (IRB No. 0032.003/658), Songkhla (IRB No. 075/2014), and Chiang Mai (IRB No. 0032.002/35859).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available. Please contact corresponding author.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Centers for Disease Control and Prevention. *Sexually transmitted disease surveillance* 2017, 2018.
- Tongtong J, Todd CS, Chonwattana W, *et al.* Prevalence and correlates of chlamydia trachomatis and neisseria gonorrhoeae by anatomic site among urban Thai men who have sex with men. *Sex Transm Dis* 2015;42:440–9.
- Jatapai A, Sirivongrangson P, Lokpichat S, *et al.* Prevalence and risk factors for Chlamydia trachomatis infection among young Thai men in 2008–2009. *Sex Transm Dis* 2013;40:241–6.
- Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect* 1999;75:3–17.
- Bernstein KT, Marcus JL, Nieri G, *et al.* Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. *J Acquir Immune Defic Syndr* 2010;53:537–43.
- Katz DA, Dombrowski JC, Bell TR, *et al.* HIV incidence among men who have sex with men after diagnosis with sexually transmitted infections. *Sex Transm Dis* 2016;43:249–54.
- Lutz AR. Screening for asymptomatic extragenital gonorrhea and chlamydia in men who have sex with men: significance, recommendations, and options for overcoming barriers to testing. *LGBT Health* 2015;2:27–34.
- Morris SR, Klausner JD, Buchbinder SP, *et al.* Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study. *Clin Infect Dis* 2006;43:1284–9.
- Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? *Clin Infect Dis* 2009;49:1798–800.
- Kent CK, Chaw JK, Wong W, *et al.* Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. *Clin Infect Dis* 2005;41:67–74.
- Bachmann LH, Johnson RE, Cheng H, *et al.* Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. *J Clin Microbiol* 2010;48:1827–32.
- Bachmann LH, Johnson RE, Cheng H, *et al.* Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. *J Clin Microbiol* 2009;47:902–7.
- Mimiaga MJ, Mayer KH, Reisner SL, *et al.* Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. *Sex Transm Dis* 2008;35:495–8.
- Schachter J, Moncada J, Liska S, *et al.* Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. *Sex Transm Dis* 2008;35:637–42.
- Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep* 2015;64:1–137.
- Ooi C, Lewis D. Updating the management of sexually transmitted infections. *Aust Prescr* 2015;38:204–8.
- Barbee LA, Dhanireddy S, Tat SA, *et al.* Barriers to Bacterial Sexually Transmitted Infection Testing of HIV-Infected Men Who Have Sex With Men Engaged in HIV Primary Care. *Sex Transm Dis* 2015;42:590–4.
- Denison HJ, Bromhead C, Grainger R, *et al.* Barriers to sexually transmitted infection testing in New Zealand: a qualitative study. *Aust N Z J Public Health* 2017;41:432–7.
- Seekaew P, Pengnonyang S, Jantarapakde J, *et al.* Characteristics and HIV epidemiologic profiles of men who have sex with men and transgender women in key population-led test and treat cohorts in Thailand. *PLoS One* 2018;13:e0203294.
- Hiransuthikul A, Pattanachaiwit S, Teeratakulpisarn N, *et al.* High subsequent and recurrent sexually transmitted infection prevalence among newly diagnosed HIV-positive Thai men who have sex with men and transgender women in the Test and Treat cohort. *Int J STD AIDS* 2019;30:956462418799213.
- Barbee LA, Dombrowski JC, Kerani R, *et al.* Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. *Sex Transm Dis* 2014;41:168–72.
- Gunn RA, O'Brien CJ, Lee MA, *et al.* Gonorrhea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997–2003. *Sex Transm Dis* 2008;35:845–8.
- Koedijk FD, van Bergen JE, Dukers-Muijers NH, *et al.* The value of testing multiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006–2010. *Int J STD AIDS* 2012;23:626–31.
- van Liere GA, Hoebe CJ, Dukers-Muijers NH. Evaluation of the anatomical site distribution of chlamydia and gonorrhoea in men who have sex with men and in high-risk women by routine testing: cross-sectional study revealing missed opportunities for treatment strategies. *Sex Transm Infect* 2014;90:58–60.
- Marcus JL, Bernstein KT, Kohn RP, *et al.* Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. *Sex Transm Dis* 2011;38:922–4.
- Chow EP, Camilleri S, Ward C, *et al.* Duration of gonorrhoea and chlamydia infection at the pharynx and rectum among men who have sex with men: a systematic review. *Sex Health* 2016;13:199–204.
- Wi T, Lahra MM, Ndowa F, *et al.* Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. *PLoS Med* 2017;14:e1002344.
- Speers DJ, Chua IJ, Manuel J, *et al.* Detection of Neisseria gonorrhoeae and Chlamydia trachomatis from pooled rectal, pharyngeal and urine specimens in men who have sex with men. *Sex Transm Infect* 2018;94:293–7.